Asher A. Qazi

Since joining Kirkland, Asher has advised on the following transactions:

• Bristol-Myers Squibb in its $90 billion acquisition of Celgene
• Bristol-Myers Squibb in the issuance of approximately ~$19 billion of senior notes to finance its acquisition of Celgene
• Bristol-Myers Squibb in exchange offers and consent solicitations for ~$20 billion of Celgene debt in connection with Bristol-Myers Squibb’s acquisition of Celgene
• AbbVie in its $63 billion acquisition of Allergan
• AbbVie in the issuance of $30 billion of senior notes to finance its acquisition of Allergan; the senior notes offering represents the largest corporate bond sale of 2019 and the fourth-largest in history
• AbbVie in exchange offers and consent solicitations for ~$22 billion of Allergan debt in connection with AbbVie’s acquisition of Allergan
• Chewy, Inc. in its $1.2 billion initial public offering
• The underwriters in connection with Visa’s $4 billion senior notes offering
• A consortium of private equity investors in the issuance of approximately ~$2.075 billion of senior notes to finance the acquisition of Inmarsat plc
• PetSmart, Inc. in the issuance of $1.2 billion of senior first notes and $1.15 billion of senior notes
• Avaya in the issuance of $1.0 billion of senior first lien notes
• The underwriters in connection with Visa’s $3.25 billion senior notes offering
• Ladder Capital Corp. in the issuance of $750 million of senior notes
• PetSmart, Inc. in connection with a Rule 144A offering by the 2020 Mandatory Exchangeable Trust of 690,000 2020 mandatory exchangeable trust securities exchangeable into Class A common stock; the offering raised gross proceeds of $690 million
• Townsquare Media in the issuance of $550 million of senior notes
• Pike Corporation in the issuance of $500 million of senior notes
• Wyndham Destinations in the issuance of $500 million of senior notes
• Owens & Minor in the issuance of $500 million of senior notes
• Ladder Capital Corp. in its ~$100 million follow-on offering and $100 million ATM program
• Pharvaris N.V. in its initial public offering